The new issue of SwissRe’s Risk Dialogue Magazine has just come out and it highlights Biognosys as an opinion-leader in the field of diagnostics. It focuses on Swiss biotech industry, especially companies pushing the boundaries of medical science.
Our article in the magazine allows us to shape the narrative of the future of blood-based diagnostics. We point out the potential of proteomics and digital biobanking in terms of health benefits for the patient. Considering the various economic aspects of diagnostics, we also present a future outlook on the market for personalized medicine and diagnostics.
Your Biognosys Team